Adipokines – removing road blocks to obesity and diabetes therapy
Abstract Prevention of obesity and therapeutic weight loss interventions have provided only limited long term success. Therefore there is an urgent need to develop novel pharmacological treatment strategies, which target mechanisms underlying positive energy balance, excessive fat accumulation and a...
Gespeichert in:
| Veröffentlicht in: | Molecular metabolism (Germany) 2014-06, Vol.3 (3), p.230-240 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 240 |
|---|---|
| container_issue | 3 |
| container_start_page | 230 |
| container_title | Molecular metabolism (Germany) |
| container_volume | 3 |
| creator | Blüher, Matthias |
| description | Abstract Prevention of obesity and therapeutic weight loss interventions have provided only limited long term success. Therefore there is an urgent need to develop novel pharmacological treatment strategies, which target mechanisms underlying positive energy balance, excessive fat accumulation and adverse fat distribution. Adipokines may have potential for future pharmacological treatment strategies of obesity and metabolic diseases, because they are involved in the regulation of appetite and satiety, energy expenditure, endothelial function, blood pressure, insulin sensitivity, adipogenesis, fat distribution and insulin secretion and others. There are important road blocks on the way from an adipokine candidate to the clinical use a therapeutic compound. Such road blocks include an incomplete understanding of the mechanism of action, resistance to a specific adipokine, side effects of the adipokine and others. This review focuses on the potential of selected adipokines as therapeutic tools or targets and discusses important road blocks, which currently prevent their clinical use. |
| doi_str_mv | 10.1016/j.molmet.2014.01.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3986498</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S2212877814000106</els_id><sourcerecordid>1540138029</sourcerecordid><originalsourceid>FETCH-LOGICAL-c584t-c0d8068c0f6bff958535e6d7e6115df32860b69e27caef8bc62b244f4e4223d43</originalsourceid><addsrcrecordid>eNqFksFu1DAQhi0EolXpGyCUI5cNtmM7zgWpWkFBqsSBch459qT1bmIvtnelvfUdeMM-CVltKYVLfbElz_-PPd9PyFtGa0aZ-rCqpzhOWGpOmagpqymVL8gp54wvdNvql0_OJ-Q85xWdl1ZKSfaanHDRio7K5pQsL5zfxLUPmKv7u19VwinufLipUjSu6sdo17kqsYo9Zl_2lQmuct70WGZBucVkNvs35NVgxoznD_sZ-fH50_Xyy-Lq2-XX5cXVwkotysJSp6nSlg6qH4ZOatlIVK5FxZh0Q8O1or3qkLfW4KB7q3jPhRgECs4bJ5oz8vHou9n2EzqLoSQzwib5yaQ9ROPh35vgb-Em7qDptBKdng3ePxik-HOLucDks8VxNAHjNgOTgrJGU97NpeJYalPMOeHw2IZROCCAFRwRwAEBUAYzgln27ukTH0V_Bv73DzgPaucxQbYeg0XnE9oCLvrnOvxvYEcfvDXjGveYV3GbwgwBGGQOFL4fYnBIARNzABhVzW-pQK_5</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1540138029</pqid></control><display><type>article</type><title>Adipokines – removing road blocks to obesity and diabetes therapy</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Blüher, Matthias</creator><creatorcontrib>Blüher, Matthias</creatorcontrib><description>Abstract Prevention of obesity and therapeutic weight loss interventions have provided only limited long term success. Therefore there is an urgent need to develop novel pharmacological treatment strategies, which target mechanisms underlying positive energy balance, excessive fat accumulation and adverse fat distribution. Adipokines may have potential for future pharmacological treatment strategies of obesity and metabolic diseases, because they are involved in the regulation of appetite and satiety, energy expenditure, endothelial function, blood pressure, insulin sensitivity, adipogenesis, fat distribution and insulin secretion and others. There are important road blocks on the way from an adipokine candidate to the clinical use a therapeutic compound. Such road blocks include an incomplete understanding of the mechanism of action, resistance to a specific adipokine, side effects of the adipokine and others. This review focuses on the potential of selected adipokines as therapeutic tools or targets and discusses important road blocks, which currently prevent their clinical use.</description><identifier>ISSN: 2212-8778</identifier><identifier>EISSN: 2212-8778</identifier><identifier>DOI: 10.1016/j.molmet.2014.01.005</identifier><identifier>PMID: 24749053</identifier><language>eng</language><publisher>Germany: Elsevier GmbH</publisher><subject>Adipokines ; Adiponectin ; Apelin ; BMP7 ; DPP4 ; Endocrinology & Metabolism ; Leptin ; Nampt/visfatin ; Nesfatin-1 ; Obesity ; Review ; Road blocks ; Therapeutic compounds ; Type 2 diabetes ; Vaspin</subject><ispartof>Molecular metabolism (Germany), 2014-06, Vol.3 (3), p.230-240</ispartof><rights>The Author</rights><rights>2014 The Author</rights><rights>2014 The Author 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c584t-c0d8068c0f6bff958535e6d7e6115df32860b69e27caef8bc62b244f4e4223d43</citedby><cites>FETCH-LOGICAL-c584t-c0d8068c0f6bff958535e6d7e6115df32860b69e27caef8bc62b244f4e4223d43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986498/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986498/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24749053$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Blüher, Matthias</creatorcontrib><title>Adipokines – removing road blocks to obesity and diabetes therapy</title><title>Molecular metabolism (Germany)</title><addtitle>Mol Metab</addtitle><description>Abstract Prevention of obesity and therapeutic weight loss interventions have provided only limited long term success. Therefore there is an urgent need to develop novel pharmacological treatment strategies, which target mechanisms underlying positive energy balance, excessive fat accumulation and adverse fat distribution. Adipokines may have potential for future pharmacological treatment strategies of obesity and metabolic diseases, because they are involved in the regulation of appetite and satiety, energy expenditure, endothelial function, blood pressure, insulin sensitivity, adipogenesis, fat distribution and insulin secretion and others. There are important road blocks on the way from an adipokine candidate to the clinical use a therapeutic compound. Such road blocks include an incomplete understanding of the mechanism of action, resistance to a specific adipokine, side effects of the adipokine and others. This review focuses on the potential of selected adipokines as therapeutic tools or targets and discusses important road blocks, which currently prevent their clinical use.</description><subject>Adipokines</subject><subject>Adiponectin</subject><subject>Apelin</subject><subject>BMP7</subject><subject>DPP4</subject><subject>Endocrinology & Metabolism</subject><subject>Leptin</subject><subject>Nampt/visfatin</subject><subject>Nesfatin-1</subject><subject>Obesity</subject><subject>Review</subject><subject>Road blocks</subject><subject>Therapeutic compounds</subject><subject>Type 2 diabetes</subject><subject>Vaspin</subject><issn>2212-8778</issn><issn>2212-8778</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNqFksFu1DAQhi0EolXpGyCUI5cNtmM7zgWpWkFBqsSBch459qT1bmIvtnelvfUdeMM-CVltKYVLfbElz_-PPd9PyFtGa0aZ-rCqpzhOWGpOmagpqymVL8gp54wvdNvql0_OJ-Q85xWdl1ZKSfaanHDRio7K5pQsL5zfxLUPmKv7u19VwinufLipUjSu6sdo17kqsYo9Zl_2lQmuct70WGZBucVkNvs35NVgxoznD_sZ-fH50_Xyy-Lq2-XX5cXVwkotysJSp6nSlg6qH4ZOatlIVK5FxZh0Q8O1or3qkLfW4KB7q3jPhRgECs4bJ5oz8vHou9n2EzqLoSQzwib5yaQ9ROPh35vgb-Em7qDptBKdng3ePxik-HOLucDks8VxNAHjNgOTgrJGU97NpeJYalPMOeHw2IZROCCAFRwRwAEBUAYzgln27ukTH0V_Bv73DzgPaucxQbYeg0XnE9oCLvrnOvxvYEcfvDXjGveYV3GbwgwBGGQOFL4fYnBIARNzABhVzW-pQK_5</recordid><startdate>20140601</startdate><enddate>20140601</enddate><creator>Blüher, Matthias</creator><general>Elsevier GmbH</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140601</creationdate><title>Adipokines – removing road blocks to obesity and diabetes therapy</title><author>Blüher, Matthias</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c584t-c0d8068c0f6bff958535e6d7e6115df32860b69e27caef8bc62b244f4e4223d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adipokines</topic><topic>Adiponectin</topic><topic>Apelin</topic><topic>BMP7</topic><topic>DPP4</topic><topic>Endocrinology & Metabolism</topic><topic>Leptin</topic><topic>Nampt/visfatin</topic><topic>Nesfatin-1</topic><topic>Obesity</topic><topic>Review</topic><topic>Road blocks</topic><topic>Therapeutic compounds</topic><topic>Type 2 diabetes</topic><topic>Vaspin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Blüher, Matthias</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular metabolism (Germany)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Blüher, Matthias</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adipokines – removing road blocks to obesity and diabetes therapy</atitle><jtitle>Molecular metabolism (Germany)</jtitle><addtitle>Mol Metab</addtitle><date>2014-06-01</date><risdate>2014</risdate><volume>3</volume><issue>3</issue><spage>230</spage><epage>240</epage><pages>230-240</pages><issn>2212-8778</issn><eissn>2212-8778</eissn><abstract>Abstract Prevention of obesity and therapeutic weight loss interventions have provided only limited long term success. Therefore there is an urgent need to develop novel pharmacological treatment strategies, which target mechanisms underlying positive energy balance, excessive fat accumulation and adverse fat distribution. Adipokines may have potential for future pharmacological treatment strategies of obesity and metabolic diseases, because they are involved in the regulation of appetite and satiety, energy expenditure, endothelial function, blood pressure, insulin sensitivity, adipogenesis, fat distribution and insulin secretion and others. There are important road blocks on the way from an adipokine candidate to the clinical use a therapeutic compound. Such road blocks include an incomplete understanding of the mechanism of action, resistance to a specific adipokine, side effects of the adipokine and others. This review focuses on the potential of selected adipokines as therapeutic tools or targets and discusses important road blocks, which currently prevent their clinical use.</abstract><cop>Germany</cop><pub>Elsevier GmbH</pub><pmid>24749053</pmid><doi>10.1016/j.molmet.2014.01.005</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2212-8778 |
| ispartof | Molecular metabolism (Germany), 2014-06, Vol.3 (3), p.230-240 |
| issn | 2212-8778 2212-8778 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3986498 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Adipokines Adiponectin Apelin BMP7 DPP4 Endocrinology & Metabolism Leptin Nampt/visfatin Nesfatin-1 Obesity Review Road blocks Therapeutic compounds Type 2 diabetes Vaspin |
| title | Adipokines – removing road blocks to obesity and diabetes therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T23%3A01%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adipokines%20%E2%80%93%20removing%20road%20blocks%20to%20obesity%20and%20diabetes%20therapy&rft.jtitle=Molecular%20metabolism%20(Germany)&rft.au=Bl%C3%BCher,%20Matthias&rft.date=2014-06-01&rft.volume=3&rft.issue=3&rft.spage=230&rft.epage=240&rft.pages=230-240&rft.issn=2212-8778&rft.eissn=2212-8778&rft_id=info:doi/10.1016/j.molmet.2014.01.005&rft_dat=%3Cproquest_pubme%3E1540138029%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1540138029&rft_id=info:pmid/24749053&rft_els_id=1_s2_0_S2212877814000106&rfr_iscdi=true |